For all our products, we offer additional services that serve to optimise processes along the entire value chain.
Be it on-site technical service, the incubation of SPF eggs or Clean Eggs adapted to the vaccine strain, the contract rearing of animals or the customised production of primary cell cultures or other precursors for final vaccine production.
Incubation of eggs is a critical factor for subsequent vaccine yield both in the use of clean eggs for inactivated vaccines and in the use of SPF eggs for live vaccine production.
We incubate well over 100 million vaccine eggs annually through our global activities in supplying both influenza vaccine manufacturers and live vaccine producers. We always do this with the aim of continuously optimizing vaccine yields for each individual virus strain in collaboration with our customers. To this end, we are also prepared to build customer-specific infrastructure as part of the contract.
Primary cell cultures
Some vaccines are produced or propagated in primary cell cultures (CEF – Chicken Embryo Fibroblasts) (for example rabies, TBE, smallpox, and Marek’s disease). The starting material for these cell cultures are incubated SPF eggs, the contents of which are further processed into a cell culture.
Both services (incubation of SPF eggs and production of cell culture under GMP conditions) are provided to our customers under contract, if required.